Dr. Park on the Benefit of Trastuzumab Deruxtecan in HER2+ Breast CancerByYeon Hee Park, MDMay 23rd 2020Yeon Hee Park, MD, discusses the utility and benefit of fam-trastuzumab deruxtecan-nxki in HER2-positive metastatic breast cancer, specifically in patients with central nervous system metastases.